Cipla Limited has informed the Exchange regarding a press release dated August 31, 2026, titled "Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)".
Cipla Ltd Press Release Aug 31 2026
Filed with NSE · · 3 pages · English
Release
Earlier from Cipla
- Cipla Ltd Press Release Jul 23 2026
- Press Release May 13 2026
- Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin HFA
- Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis
- Cipla strengthens US portfolio with the launch of generic Saxenda(R) (Liraglutide Injection) for weight management therapy
Later from Cipla
- Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US
- Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda in the US
- Cipla Limited has informed the Exchange regarding a press release dated October 27, 2026, titled "Q2FY27 Financial Results".
Follow Cipla into a list and get an email when it puts out news.
Follow Cipla